> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Will Meet with Petros on Stendra Labeling
- URL: https://www.fdaweb.com/fda-will-meet-with-petros-on-stendra-labeling/
- Published: 2021-07-27T12:00:00.000Z
- Updated: 2026-09-14T17:07:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149797

FDA says it will meet with Petros Pharmaceuticals to discuss expansions and modifications to labeling for the company’s Stendra (avanafil) erectile dysfunction medication. The company [says](https://www.marketwatch.com/press-release/fda-grants-meeting-to-petros-pharmaceuticals-to-discuss-label-expansion-of-erectile-dysfunction-drug-stendra-2021-07-27?tesla=y&ref=fdaweb.com) the meeting is scheduled for 9/2021.

Petros says it is proposing that the time interval between administration of Stendra and nitrates be revised to provide greater specificity across the product strengths and more accurately reflect the available clinical evidence.

Petros says it also has started activities it hopes will lead to FDA considering moving Stendra from prescription to over-the-counter status.